Alnylam Pharma (ALNY) Tops Q4 EPS by 16c
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Price: $312.78 +3.68%
EPS Growth %: +409.4%
Financial Fact:
General and administrative: 17.99M
Today's EPS Names:
CRMT, More
EPS Growth %: +409.4%
Financial Fact:
General and administrative: 17.99M
Today's EPS Names:
CRMT, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q4 EPS of ($1.60), $0.16 better than the analyst estimate of ($1.76). Revenue for the quarter came in at $163.6 million versus the consensus estimate of $146.07 million.
- – Provides 2021 Combined Net Product Revenue Guidance of $610-660 Million, in addition to Collaboration & Royalty Revenue and Operating Expense Guidance –
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Alnylam Pharmaceuticals (ALNY) PT Lowered to $470 at H.C. Wainwright
- Franklin Covey (FC) Misses Q3 EPS by 2c, lowers Guidance
- Constellation Brands (STZ) Tops Q1 EPS by 18c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
